Introduction
Bladder cancer is the seventh most common cancer in the UK. It is 3-4 times more common in men than in women. In the UK in 2011 it was the fourth most common cancer in men and the thirteenth most common in women. There were 10,399 people diagnosed with bladder cancer and 5,081 deaths from bladder cancer in 2011. The majority of cases occur in people aged over 60.
Bladder cancer is usually identified on the basis of visible blood in the urine or blood found on urine testing, but emergency admission is a common way for bladder cancer to present, and is often associated with a poor prognosis.
Most bladder cancers (75-80%) do not involve the muscle wall of the bladder and are usually treated by telescopic removal of the cancer (transurethral resection of bladder tumour [TURBT]), often followed by instillation of chemotherapy or vaccine-based therapy into the bladder, with prolonged telescopic checking of the bladder (cystoscopy) as follow-up. Some people in this group who are at higher risk are treated with major surgery to remove the bladder (cystectomy). People with cancer in or through the bladder muscle wall may be treated with intent to cure using chemotherapy, cystectomy or radiotherapy, and those who have cancer too advanced to cure may be treated with radiotherapy and chemotherapy.
The involvement of the urogenital tract and the nature of the treatments gives this cancer a strong psychological impact, in addition to the physical impact of the disease and its treatments, which is often profound. The prevalence of the condition and the nature of its management make bladder cancer one of the most expensive cancers for the NHS.
There is thought to be considerable variation across the NHS in the diagnosis and management of bladder cancer and the provision of care to people who have it. There is evidence that the patient experience for people with bladder cancer is worse than that for people with other cancers. It does not cover people aged under 18 or adults with bladder sarcoma, urothelial cancer of the upper urinary tract, or secondary bladder or urethral cancer (for example bowel or cervix cancer spreading into the bladder).
Drug recommendations
The guideline will assume that prescribers will use a drug's summary of product characteristics to inform decisions made with individual patients.
This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if there is good evidence to support that use. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. The patient 
Patient-centred care
This guideline offers best practice advice on the care of adults with bladder cancer. 
Strength of recommendations
Some recommendations can be made with more certainty than others. The
Guideline Development Group makes a recommendation based on the tradeoff between the benefits and harms of an intervention, taking into account the quality of the underpinning evidence. For some interventions, the Guideline Development Group is confident that, given the information it has looked at, most patients would choose the intervention. The wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made (the strength of the recommendation).
For all recommendations, NICE expects that there is discussion with the patient about the risks and benefits of the interventions, and their values and preferences. This discussion aims to help them to reach a fully informed decision (see also 'Patient-centred care').
Interventions that must (or must not) be used
We usually use 'must' or 'must not' only if there is a legal duty to apply the recommendation. Occasionally we use 'must' (or 'must not') if the consequences of not following the recommendation could be extremely serious or potentially life threatening.
Interventions that should (or should not) be used -a 'strong' recommendation
We use 'offer' (and similar words such as 'refer' or 'advise') when we are confident that, for the vast majority of patients, an intervention will do more good than harm, and be cost effective. We use similar forms of words (for example, 'Do not offer…') when we are confident that an intervention will not be of benefit for most patients.
Interventions that could be used
We use 'consider' when we are confident that an intervention will do more good than harm for most patients, and be cost effective, but other options may be similarly cost effective. The choice of intervention, and whether or not to have the intervention at all, is more likely to depend on the patient's values and preferences than for a strong recommendation, and so the healthcare professional should spend more time considering and discussing the options with the patient.
Key priorities for implementation
The following recommendations have been identified as priorities for implementation. The full list of recommendations is in section 1. 
Recommendations
The following guidance is based on the best available evidence. The full guideline [hyperlink to be added for final publication] gives details of the methods and the evidence used to develop the guidance.  acts as the key worker to address the person's information and care needs  has experience and training in bladder cancer care.  how to find information about returning to work after treatment for cancer  how to find information about financial support (such as free prescriptions and industrial compensation schemes).  impact on quality of life, body image, and sexual and urinary function. High-risk non-muscle-invasive bladder cancer
Terms used in this guideline

Intravesical BCG
1.3.24
Offer people with high-risk non-muscle-invasive bladder cancer cystoscopic follow-up:
 every 3 months for the first 2 years, then  every 6 months for the next 2 years, then
Managing muscle-invasive bladder cancer
1.4.1 Ensure that a specialist multidisciplinary bladder cancer team reviews all cases of muscle-invasive bladder cancer and that the review includes histopathology, imaging and discussion of treatment options.
1.4.2
Offer neoadjuvant chemotherapy using a cisplatin combination regimen before radical cystectomy or radical radiotherapy to people with newly diagnosed muscle-invasive urothelial cancer of the bladder for whom cisplatin-based chemotherapy is suitable. Ensure that they have an opportunity to discuss the risks and benefits with an oncologist who treats bladder cancer.  their renal function is adequate (GFR higher than 60 ml/min) and  they are otherwise physically fit (have a WHO performance status of 0 or 1). 
Research recommendations
The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future. The Guideline Development Group's full set of research recommendations is detailed in the full guideline [hyperlink to be inserted at publication].
Patient satisfaction
What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?
Why this is important
The urological cancers grouping (which includes bladder cancer but excludes prostate cancer) has consistently appeared near the bottom of the 
BCG or primary cystectomy in high-risk non-muscleinvasive bladder cancer
Is primary radical cystectomy more effective than primary intravesical BCG in high-risk non-muscle-invasive bladder cancer in terms of quality of life and cancer-specific outcomes?
Why this is important
Options for people with high-risk non-muscle-invasive bladder cancer include cystoscopy surveillance, BCG immunotherapy or radical surgery. To date, these have not been directly compared across the same population to understand their relative benefits.
Bladder-sparing approaches avoid major surgery, but have a greater risk of cancer progression. However, the potential advantage of maintaining quality of life compared to cystectomy may be offset by continuing concern about cancer progression and morbidity of treatment. Primary cystectomy may improve survival, however it has high short-term risks and life-changing consequences. It will be overtreatment for those people whose cancer would not have progressed.
Follow-up of high-risk non-muscle-invasive bladder cancer
In people with high-risk non-muscle-invasive bladder cancer, are these 2 follow-up regimens equally effective in terms of identification of progression, cost effectiveness and health-related quality of life?
 Cystoscopic follow-up at 3, 6, 12, 18, 24, 36 and 48 months, and then annually, interspersed with non-invasive urinary tests.
Why this is important
Cystoscopy is currently the standard of care for follow-up of people with high risk non-muscle-invasive bladder cancer. Regular cystoscopy may be associated with anxiety, procedural discomfort to the person and significant costs to the NHS.
Urine tests based on a variety of technologies (including cytology, FISH and proteomic platforms) can detect high-grade recurrence, raising the possibility that one or more of these tests could be used to reduce the frequency of cystoscopy. This could improve acceptability to patients and reduce costs to the NHS without increasing the risk of disease progression.
There is a lack of evidence on the optimal frequency of follow-up and whether the frequency of cystoscopy follow-up can safely be reduced by substitution of urinary tests.
Biomarkers for treatment selection
In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of biomarkers to select treatment produce better outcomes than treatment selected without biomarkers?
Why this is important
Response to surgery or radiotherapy is difficult to predict for individuals. There is variation not only in the cure rates for patients with muscle-invasive bladder cancer treated with either surgery or radiotherapy, but also in the side effects experienced during and after treatment. The usefulness of current biomarkers in predicting treatment outcomes for individual patients has not been clearly 
Standard care after treatment for organ-confined muscle-invasive bladder cancer is scheduled follow-up at intervals set out by the treating team.
Although this can be reassuring for both the patient and the treating team, it is not known whether scheduled follow-up offers clinical benefit compared with symptom-based review, which is increasingly used for people with other cancers. Moreover, there are significant costs associated with follow-up. The current evidence about follow-up is confined to cystectomy. There is no evidence concerning follow-up after radiotherapy. In addition, the evidence on radiological follow-up uses mainly outdated imaging techniques.
Other information
Scope and how this guideline was developed
NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover.
